Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
Glucosamine (GlcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of
chitosan with recently reported immunoregulatory capacity and anti-inflammatory effect and
was administrated orally in osteoarthritis and atopic dermatitis therapy. Given the Oral
lichen planus (OLP) T-cell-mediated pathogenesis; this drug seems to be a promising
therapeutic option. The investigators compared clinical effectiveness of Glucosamine combined
with two topical corticosteroid regimens to that of topical corticosteroid alone in
symptomatic OLP and investigated therapeutic mechanism by examining treatment effect on
expression of inhibitor kappa kinase alpha (IKKα) and interleukin-8 (IL-8) in OLP lesions.